Lupin Pharma

This sponsor has funded 4 studies across 14 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
8044 Finalised EU RMP category 3 Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and... Yes Yes
9871 Finalised EU RMP category 1 Evaluation of the Effectiveness of Risk Minimization Measures: Trimetazidine Drug Utilization Study in European Countries using databases – analysis... No Yes
12241 Finalised EU RMP category 1 Drug utilisation study (DUS) on flupirtine-containing medicinal products Yes Yes
37943 Ongoing EU RMP category 3 An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients with... Yes No

PAS by Risk Management Plan (RMP) requirement

Lupin Pharma

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.